Reportedly, the entire facility is spread across 5000 sqft for formulation, development and analytical development and is designed and equipped to meet the stringent international standards.
Bafna Pharmaceuticals said that the new facility is in complete compliance with cGMP, eGLP & ICII guidelines in conducting the R&D activities along with full regulatory compliance to EU-DMF and US-DMF.
Through this facility , Bafna Pharmaceuticals is expected to file dossiers for US, UK and European markets. The overall objective of this facility is to develop the pharmaceutical products on contract basis and to design and develop the products indigenously for the ever expanding pharma market.
This facility will offer a one stop solution right from development to formulation to dossier making to commercial production and in the long-run, the facility is going to be a completely independent profit making center, said the company.
Mahaveer Chand, chairman and managing director of Bafna Pharmaceuticals, said: “With advanced R&D equipments, testing instruments and process control facilities, the R&D center is equipped to manufacture new products from laboratory scale to validation batches.
“The R&D center has qualified and competent research scientists,who have developed many innovations in the manufacture of formulations, to meet the various requirements of the global market. We strongly believe that with the launch of the new R&D centre we will significantly elevate our efforts in enhancing and developing new products and exceed our customer expectations.”